Your browser is no longer supported. Please, upgrade your browser.
Johnson & Johnson
IndexDJIA S&P500 P/E17.83 EPS (ttm)5.70 Insider Own0.01% Shs Outstand2.78B Perf Week0.43%
Market Cap282.64B Forward P/E15.58 EPS next Y6.53 Insider Trans-1.74% Shs Float2.78B Perf Month1.52%
Income16.32B PEG2.99 EPS next Q1.53 Inst Own67.40% Short Float0.94% Perf Quarter-5.25%
Sales74.33B P/S3.80 EPS this Y18.50% Inst Trans-0.86% Short Ratio2.82 Perf Half Y-0.32%
Book/sh24.96 P/B4.07 EPS next Y5.21% ROA15.80% Target Price109.14 Perf Year11.90%
Cash/sh11.90 P/C8.54 EPS next 5Y5.96% ROE28.00% 52W Range89.78 - 108.23 Perf YTD-2.11%
Dividend2.80 P/FCF40.44 EPS past 5Y5.30% ROI18.40% 52W High-6.08% Beta0.57
Dividend %2.75% Quick Ratio2.00 Sales past 5Y3.70% Gross Margin69.40% 52W Low13.22% ATR1.39
Employees126500 Current Ratio2.40 Sales Q/Q-0.60% Oper. Margin29.10% RSI (14)51.44 Volatility1.17% 1.38%
OptionableYes Debt/Eq0.27 EPS Q/Q-27.60% Profit Margin28.30% Rel Volume0.93 Prev Close102.34
ShortableYes LT Debt/Eq0.22 EarningsJan 20 BMO Payout36.90% Avg Volume9.24M Price101.65
Recom2.50 SMA201.05% SMA50-0.45% SMA200-0.72% Volume8,637,135 Change-0.67%
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
Apr-12-13Reiterated Deutsche Bank Buy $82 → $87
Mar-26-13Reiterated UBS Buy $81 → $87
Jan-11-13Reiterated UBS Buy $76 → $78
Jan-04-13Upgrade Deutsche Bank Hold → Buy $75 → $82
Nov-20-12Initiated Stifel Nicolaus Hold
Jul-18-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
Apr-18-12Reiterated UBS Buy $71 → $70
Dec-12-11Reiterated UBS Buy $72 → $69
Mar-04-15 06:27PM  J&J nearing deal to buy cancer drug maker Pharmacyclics - FT Reuters
06:24PM  Report: J&J close to deal to buy partner Pharmacyclics AP
06:02PM  J&J nears deal for cancer drugmaker at Financial Times
05:48PM  Biz Break: Pharmacyclics to sell in biggest biotech deal of the year, reports say at San Jose Mercury News
05:23PM  J&J Said to Agree to Acquire Pharmacyclics for Cancer Drug at Bloomberg
05:20PM  After-hours buzz: Vivint, H&R Block, Encana & more at CNBC
04:33PM  Johnson & Johnson near deal for Pharmacyclics: FT at MarketWatch
01:44PM  Three trades to go before the closing bell at CNBC
12:59PM  FMHR Final Trade: ESRX, EXXI & JNJ CNBC
11:50AM  GTx narrows annual loss, continues trials at
10:50AM  Geron's Q4 Loss Narrows Y/Y, Announces Restructuring Plan - Analyst Blog Zacks
Mar-03-15 11:44PM  Johnson & Johnson's Zytiga May Get a Boost at
11:26AM  Cardinal Health Set to Buy Cordis, Shares Hit 52-Week High - Analyst Blog Zacks
10:33AM  Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog Zacks
Mar-02-15 06:12PM  Cramer: Market headed for froth-time to sell? at CNBC
05:48PM  McDermott, Nutrisystem shares rally on small-cap earnings surprises at MarketWatch
05:14PM  US STOCKS-Wall St. rallies; Nasdaq hits highest level since 2000 Reuters
04:30PM  Cardinal Health, Inc. -- Moody's: Cardinal Health's planned acquisition of Cordis boosts its lower cost medical products strategy at Moody's
04:29PM  US STOCKS-U.S. stocks rally; Nasdaq hits highest level since 2000 Reuters
03:29PM  US STOCKS-Wall St advances after data and deals; Nasdaq hits 5,000 Reuters
02:58PM  Cardinal to Buy J&J's Heart Business at The Wall Street Journal
02:09PM  Why Cardinal Health Decided to Buy J&Js Cordis Unit at Bloomberg
01:33PM  US STOCKS-Wall St advances, with Nasdaq hitting 5,000, after data Reuters
01:21PM  Cardinal Health Pops To New High On J&J Heart Business Acquisition at
01:00PM  What's in Store for Geron (GERN) this Earnings Season? - Analyst Blog Zacks
11:35AM  Cardinal Health buying Johnson & Johnson cardiovascular unit for $1.9B at
10:36AM  Cardinal Health to buy J&J unit for about $1.94 billion at Los Angeles Times
10:35AM  Boston Scientific buys men's health business of AMS for $1.65B at
10:30AM  Hedge funds cut Apple and these other VIP stocks at CNBC
10:30AM  Looking for European Dividends? Say Oui to the France ETF ETF Trends
10:05AM  Elliott Management adds new position in Allergan Market Realist
09:41AM  US STOCKS-Wall St inches up in wake of February rally Reuters
09:33AM  Cardinal Health offers to buy J&J unit for about $1.94B AP
09:16AM  US STOCKS-Wall St set for flat open after February rally Reuters
09:05AM  Lumber Liquidators melts; J&J deal; Costco's new credit cards Yahoo Finance
08:36AM  Cardinal Health To Buy J&J Cardiology Device Unit at Investor's Business Daily
07:56AM  March market madness?; Lumber Liquidators' shellacking; Warren Buffett successor hints Yahoo Finance
07:54AM  Cardinal Health to Buy J&Js Cordis Unit for $1.94 Billion at Bloomberg
07:50AM  Early movers: BRK.B, AAPL, LL, CAH, BSX & more at CNBC
07:48AM  Cardinal to buy J&J vascular technology unit Cordis for $1.9 bln Reuters
07:40AM  Cardinal Health to buy Johnson & Johnson's Cordis business for nearly $2 billion at MarketWatch
07:30AM  Johnson & Johnson Announces Binding Offer from Cardinal Health to Acquire Cordis PR Newswire
Mar-01-15 07:01PM  Amgen says Kyprolis doubles progression-free survival vs Velcade Reuters
Feb-27-15 12:10PM  Who Might Buy Puma Biotechnology? at
11:31AM  Cramer: Pharmacyclics-Johnson & Johnson Deal Unlikely at This Price at TheStreet
09:10AM  Gadfly Pharma Investor Shkreli Starts Anew After Ousting From Retrophin at Forbes
08:04AM  Why should you invest in healthcare ETFs? Market Realist
07:00AM  Compelling Financial Benefit in Valeant's Latest Buy Morningstar
06:43AM  Decision on Ebola mass vaccination in August at earliest - WHO Reuters
05:42AM  Decision on widespread Ebola vaccination in August at earliest - WHO Reuters
Feb-26-15 07:08PM  10-K for Johnson & Johnson Company Spotlight
06:22PM  Cramer: 'I'm a happy camper'-Thanks, Europe! at CNBC
05:17PM  Idaho House panel endorses banning contact lens price floors AP
09:56AM  Medivation Tops Q4 Views On Strong Xtandi Results at Investor's Business Daily
09:00AM  Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog Zacks
08:00AM  Johnson & Johnson Announces Formation of New Health and Wellness Platform Designed to Transform Health Care Delivery and Improve the Patient Experience PR Newswire
05:07AM  South Carolina court orders J&J to pay $136 mln in Risperdal case Reuters
Feb-25-15 03:31AM  Biosimilar copies of blockbuster drug launch in major EU markets Reuters
Feb-24-15 05:06PM  Big pharma diversifies business to mitigate patent risk Market Realist
04:52PM  Johnson & Johnson Loses Trial Over Risperdal And Male Breasts at The Wall Street Journal
02:27PM  Brain-Altering Devices May Supplant Drugs -- And Pharma Is OK With That at Forbes
06:10AM  JOHNSON & JOHNSON Files SEC form 10-K, Annual Report EDGAR Online
Feb-23-15 04:03PM  Healthcare Breaks Out: More Upside Is Ahead at
01:57PM  3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis Benzinga
Feb-21-15 06:00AM  [video]'Mad Money' Lightning Round: J&J Must Get Its Game Back at TheStreet
Feb-20-15 07:00PM  Cramer: This stock is on a run CNBC
06:20PM  New conference focused on early-stage funding comes to Houston at American City Business Journals
12:28PM  What it takes to be called big pharma Market Realist
Feb-19-15 10:50AM  Boston Scientific Settles $7.2B J&J Suit for $600M, Stock Up - Analyst Blog Zacks
09:50AM  Pharmacyclics Misses on Q4 Earnings, Reiterates 2015 View - Analyst Blog Zacks
09:30AM  The Zacks Analyst Blog Highlights: TIAA-CREF Social Choice Equity Retail, Johnson & Johnson, Procter & Gamble, Domini Social Equity Investor and Apple - Press Releases Zacks
Feb-18-15 06:21PM  Can Boston Scientific Finally Move on From Its Guidant Mistake? at The Wall Street Journal
04:44PM  Boston Scientific Closes Up 12% Benzinga
02:42PM  Boston Scientific Soars 11% After Settling Dispute With Johnson & Johnson Benzinga
11:45AM  Social Responsible Investing Can Be Profitable Too: 2 Funds to Buy - Mutual Fund Commentary Zacks
10:59AM  Why Big Pharma Must Cure Its Bad Rap at Forbes
10:24AM  Sterne Agree Weighs In On Boston Scientific-Johnson & Johnson Litigation Settlement Benzinga
09:16AM  Stock Futures Show Mild Losses; Boston Scientific Bolts Higher at Investor's Business Daily
09:14AM  Boston Scientific (BSX) Stock Higher Today After Johnson & Johnson Suit Settlement at TheStreet
02:34AM  ITC Call Costs Jump as Stock Climbs to 2-Month High on Valuation at Bloomberg
12:56AM  PRESS DIGEST-New York Times business news - Feb 18 Reuters
12:12AM  Boston Scientific to Pay J&J $600 Million to Settle Guidant Suit at The Wall Street Journal
Feb-17-15 06:20PM  Boston Scientific will pay Johnson & Johnson $600M AP
05:40PM  Boston Scientific, J&J Settle Guidant Suit at The Wall Street Journal
05:40PM  Fossil Group shares drop after earnings miss at MarketWatch
05:17PM  Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog Zacks
05:02PM  Boston Scientific settles $7.2B lawsuit brought by Johnson & Johnson for $600M at American City Business Journals
04:31PM  Boston Scientific settles J&J lawsuit over Guidant at MarketWatch
04:20PM  JNJ & BSX settle CNBC
04:01PM  The 4 Stocks That Buoyed the DJIA on Tuesday at 24/7 Wall St.
12:58PM  FMHR Final Trade: LOW, ICE, JNJ & CVLT CNBC
07:00AM  Mika Brzezinski goes Oprahor wants to be Sheryl Sandberg? at Fortune
Feb-16-15 08:36AM  If Pfizer's Right, Hospira Biosimilar Gold Rush Begins at Forbes
07:00AM  Corporate Tax Reform's Winners and Losers Morningstar
Feb-13-15 03:06PM  Brookdales 4Q14 results take a hit: Lower occupancy to blame Market Realist
11:18AM  Johnson & Johnson Faces Pressure From U.S. Patent Office Benzinga
07:50AM  Thursdays Notable Options Activity: Utilities From Hero to Zero Yahoo Finance Contributors
05:50AM  Companies pushing Ebola vaccines through trials won't let up, says Novavax CEO at American City Business Journals
Feb-12-15 06:37PM  Johnson & Johnson projects aim to spot who'll get a disease AP
04:00PM  For many of China's biotech brains-in-exile, it's time to come home Reuters
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stoffels PaulusChief Scientific OfficerFeb 09Option Exercise0.0029,073064,647Feb 11 08:16 PM
Caruso Dominic JVP, Finance; CFOFeb 09Option Exercise0.0031,5370101,324Feb 11 08:16 PM
Fasolo PeterVP, Global Human ResourcesFeb 09Option Exercise0.0020,935042,109Feb 11 08:16 PM
Gorsky AlexChairman, CEOFeb 09Option Exercise0.0042,1120130,173Feb 11 08:17 PM
COSGROVE STEPHEN JCorporate ControllerJan 16Option Exercise0.0011,1080101,402Jan 21 05:48 PM
Ullmann Michael HVP, General CounselJan 16Option Exercise0.008,949075,628Jan 21 05:48 PM
Caruso Dominic JVP, Finance; CFOJan 16Option Exercise0.0012,615074,216Jan 21 05:48 PM
Gorsky AlexChairman, CEOJan 16Option Exercise0.0016,845094,425Jan 21 05:48 PM
Stoffels PaulusChief Scientific OfficerJan 16Option Exercise0.0011,629039,539Jan 21 05:48 PM
Fasolo PeterVP, Global Human ResourcesJan 16Option Exercise0.008,374024,336Jan 21 05:48 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,689031,210Dec 19 04:37 PM
JOHNSON & JOHNSON10% OwnerNov 12Buy18.0040,000720,0003,077,005Nov 12 03:06 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Option Exercise66.182,490164,78892,784Nov 07 04:49 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Sale108.552,490270,29390,294Nov 07 04:49 PM
CULLEN JAMESDirectorSep 10Sale104.122,446254,6721,489Sep 11 02:19 PM
Caruso Dominic JVP, Finance; CFOAug 21Option Exercise66.1830,0001,985,40091,600Aug 25 04:35 PM
Caruso Dominic JVP, Finance; CFOAug 21Sale104.3030,0003,129,06961,600Aug 25 04:35 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Option Exercise66.1822,0001,455,960112,294May 06 06:10 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Sale100.0522,0002,201,10090,294May 06 06:10 PM
JOHNSON & JOHNSON10% OwnerMay 01Option Exercise5.1672,690375,0801,773,730May 05 02:19 PM
COSGROVE STEPHEN JCorporate ControllerApr 25Option Exercise66.181,51099,93291,293Apr 28 05:03 PM
Fasolo PeterVP, Global Human ResourcesMar 14Sale93.156,824635,64015,647Mar 17 06:10 PM